体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析*

doi:10.3969/j.issn.1672-5069.2024.03.009

Abstract

Abstract: Objective The aim of this study was to investigate the prevalence and risk factors of non-alcoholic fatty liver diseases (NAFLD) in persons at normal physical examination. Methods A total of 14415 individuals participated annually physical examination in our hospital in 2022, and all had normal routine physical examination (PE), including anthropology, hematology, biochemical parameters and ultrasonography. The univariate and multivariate Logistic regression analysis was applied to reveal the risk factors for the occurrence of NAFLD. Results Out of the 14415 individuals participating PE, the NAFLD was found in 5016 cases(34.8%), with the prevalence of 47.0% in male, much higher than 21.8%(P＜0.05) in female; the body mass index (BMI), white blood cell count and platelet count in patients with NAFLD were (25.8±3.0)kg/m², (7.0±1.7)×10⁹/L and (263.4±62.4)×10⁹/L, all significantly greater than [(21.9±2.6)kg/m², (6.3±1.6)×10⁹/L and (253.3±55.4)×10⁹/L, respectively, P＜0.05] in individuals without NAFLD; serum ALP, GGT, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDLC), glucose (Glu) and uric acid (UA) levels in patients with NAFLD were significantly higher than in those without NAFLD (P＜0.05), while serum high density lipoprotein cholesterol (HDLC) level was much lower than in those without NAFLD (P＜0.05); the univariate Logistic regression analysis showed that the age, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), ALT, ALP, GGT, TC, TG, LDLC, Glu, UA, white blood cell count and platelet count were all the factors affecting NAFLD occurrence (P ＜ 0.05), while the HDLC level was the protective factor (P＜0.05); the multivariate Logistic regression analysis demonstrated that the age (OR=1.028), BMI(OR=1.607), DBP(OR=1.039), ALP(OR=1.029), TG(OR=2.847), Glu(OR=2.716) and UA(OR=1.005) were the independent risk factors impacting the NAFLD occurrence (P＜0.05), while serum HDL-C level(OR=0.054) was still the protective factor(P＜0.05). Conclusion The prevalence of NAFLD is high in population at PE, and the obesity, hyperlipidemia and hyperuricemia are all the risk factors, which should be properly managed.

Key words: Non-alcoholic fatty liver diseases, Physical examination, Prevalence, Risk factor

Nong Xiaoli, Chen Fei, Zhan Haohong, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in individuals for physical examination[J]. Journal of Practical Hepatology, 2024, 27(3): 353-356.

References

[1] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic. Hepatology, 2019,69(6):2672-2682.
[2] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018,67(1):123-133.
[3] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020,71(5):1851-1864.
[4] 张薇, 魏来. 非酒精性脂肪性肝病在亚洲的流行情况. 中华肝脏病杂志, 2013,21(11):801-804.
[5] Zhao X, Wang J, Wei J, et al. Gamma-glutamyl transpeptidase to platelet ratio predicts liver injury in hepatitis B e antigen-negative chronic hepatitis B patients with normal alanine aminotransferase. J Clin Translat Hepatol, 2022,10(2):247-253.
[6] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016,64(6):1388-1402.
[7] 中国医疗保健国际交流促进会营养与代谢管理分会, 中国营养学会临床营养分会, 中华医学会糖尿病学分会, 等. 中国超重/肥胖医学营养治疗指南(2021年). 中国医学前沿杂志(电子版), 2021,13(11):1-55.
[8] 中国高血压防治指南修订委员会, 中国高血压联盟, 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等. 中国高血压防治指南( 2018年修订版). 中国心血管杂志, 2019,24(1):24-56.
[9] Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev, 2018,2018:9547613.
[10] Rinella M E. Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015,313(22):2263-2273.
[11] Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64(1):73-84.
[12] Sporea I, Popescu A, Dumitra cu D, et al. Nonalcoholic fatty liver disease: status quo. J Gastrointest Liver Dis, 2018,27(4):439-448.
[13] 葛辉, 陈君, 孙毅明, 等. 广州市健康体检人群NAFLD患病情况及相关危险因素分析. 中华医学杂志, 2016,96(46):3706-3709.
[14] Kim D, Kim Y, Lee J, et al. Estrogen-related receptor γ controls sterol regulatory element-binding protein-1c expression and alcoholic fatty liver. Biochim Biophys Acta Mol Cell Biol Lipids, 2019,1864(12):158521.
[15] Zhou Y, Tian N, Li P, et al. The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: a cross-sectional study. Eur J Gastroenterol Hepatol, 2022,34(11):1158-1164.
[16] Zhao Y, Xia J, He H, et al. Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. Front Endocrinol, 2022,13:981196.
[17] Huang H, Wang Q, Shi X, et al. Association between monocyte to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: a cross-Sectional study. Mediat Inflamma, 2021,2021:6642246.
[18] Diehl A M, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. New Engl J Med, 2017,377(21):2063-2072.
[19] 宋崑, 许海燕, 陆作林, 等. 成年体检人群中白细胞计数与NAFLD的关联. 中华健康管理学杂志, 2017,11(3):201-205.
[20] Kim H, Chung G E, Park I Y, et al. Elevated peripheral blood monocyte fraction in nonalcoholic fatty liver disease. Tohoku J Exp Med, 2011,223(3):227-233.
[21] Xiong T, Zhong C, Sun G, et al. Early maternal circulating alkaline phosphatase with subsequent gestational diabetes mellitus and glucose regulation: a prospective cohort study in China. Endocrine, 2019,65(2):295-303.
[22] Ali A H, Petroski G F, Diaz-Arias A A, et al. A model incorporating serum alkaline phosphatase for prediction of liver fibrosis in adults with obesity and nonalcoholic fatty liver disease. J Clin Med, 2021,10(15):1023-1028.

Prevalence and risk factors of nonalcoholic fatty liver disease in individuals for physical examination

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Sun Shilei, Liu Cuicui, Li Shuguang, et al. Changes of serum fibroblast growth factor-21 and secreted frizzled related protein 5 in patients with non-alcoholic fatty liver disease and T2DM [J]. Journal of Practical Hepatology, 2024, 27(3): 357-360.
[2]	Wang Xiuqi, Zhang Yu, Wu Yifan, et al. Clinical features and risk factors of hepatic myelopathy after TIPS for in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(3): 410-413.
[3]	Zhu Chunfen, Ren Chunlin, Guo Xia. Clinical feature, electrocardiogram findings and risk factors in patients with cirrhotic cardiomyopathy [J]. Journal of Practical Hepatology, 2024, 27(3): 414-417.
[4]	Shi Ameng, He Xin, Wang Ying, et al. Prevalence and risk factors of gallstones in non-obese individuals for physical examination [J]. Journal of Practical Hepatology, 2024, 27(3): 458-461.
[5]	Gao Yang, Zhang Jing, Lu Xuanlin. Changes of serum IL-1RA, CTRP13 and CK-18 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 185-188.
[6]	Li Min, Zhang Li, Zeng Ai, et al.. Liver fibrosis in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 193-197.
[7]	Zheng Bo, Halida.Xiaerfuhazi, Tan Li. Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis [J]. Journal of Practical Hepatology, 2024, 27(2): 198-201.
[8]	Zhang Tianqi, Wang Min, Yang Na, et al.. Drug-induced liver injury in ICU patients with severe infection receiving tigecycline therapy: An analysis of 74 cases [J]. Journal of Practical Hepatology, 2024, 27(2): 214-217.
[9]	Jin Keke, Ding Huiguo. Risk and anticoagulation management of cirrhotic patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2024, 27(1): 3-6.
[10]	Wang Wenchuan, Liang Kuopeng, He Ruiling, et al. Prevalence of non-alcoholic fatty liver diseases in patients with type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(1): 40-43.
[11]	Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.
[12]	Shi Yiwen, Fan Jiangao. Epidemiologic status of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 777-780.
[13]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[14]	Shao Xiaoru, Zhou Xiao, Ge Yingying. Diagnosis of coronary atherosclerotic heart disease in patients with nonalcoholic fatty liver disease by CCTA and¹⁸F-FDG intake [J]. Journal of Practical Hepatology, 2023, 26(6): 811-814.
[15]	Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study [J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.